Arctic Bioscience AS (FRA:9TD) ROCE %: -15.76% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:9TD Arctic Bioscience AS FRA:9TD
59 GF Score
Price €0.24
GF Value €1.02
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Arctic Bioscience AS ROCE %?

Arctic Bioscience AS FRA:9TD -7.95% 59 ROCE % is -15.76% as of Dec. 2025. GuruFocus rates FRA:9TD with a GF Score™ of 59/100 and a GF Value™ of €1.02 (Possible Value Trap). The stock has 6 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Arctic Bioscience AS's annualized ROCE % for the quarter that ended in Dec. 2025 was -15.76%.

Arctic Bioscience AS  (FRA:9TD) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Arctic Bioscience AS ROCE % Related Terms

Arctic Bioscience AS ROCE % Historical Data

* Premium members only.

The historical data trend for Arctic Bioscience AS's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arctic Bioscience AS ROCE % Chart

Arctic Bioscience AS Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial -21.77 -11.01 -15.45 -18.73 -15.38

Arctic Bioscience AS Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -17.89 -17.93 -19.80 -13.86 -15.76
FRA:9TD
59GF Score
Arctic Bioscience AS FRA:9TD
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arctic Bioscience AS ROCE % Calculation

Arctic Bioscience AS's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-2.699/( ( (23.81 - 5.748) + (24.052 - 7.011) )/ 2 )
=-2.699/( (18.062+17.041)/ 2 )
=-2.699/17.5515
=-15.38 %

Arctic Bioscience AS's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-2.862/( ( (25.043 - 5.765) + (24.052 - 7.011) )/ 2 )
=-2.862/( ( 19.278 + 17.041 )/ 2 )
=-2.862/18.1595
=-15.76 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -15.76% mean?
Arctic Bioscience AS (FRA:9TD) has a ROCE % of -15.76% as of Dec. 2025.
Is Arctic Bioscience AS's ROCE % too high?
Arctic Bioscience AS's current ROCE % is -15.76%. Overall, Arctic Bioscience AS has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Arctic Bioscience AS's ROCE % compare to VRTX and REGN?
Arctic Bioscience AS's ROCE % of -15.76% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Arctic Bioscience AS's current ROCE % is -15.76%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arctic Bioscience AS stock overvalued right now?
Based on GuruFocus' analysis, Arctic Bioscience AS (FRA:9TD) is currently considered Possible Value Trap. The stock's GF Value™ is €1.02, compared to a current price of €0.24 — trading 76.2% below its estimated fair value. The current ROCE % is -15.76%. Arctic Bioscience AS's overall GF Score™ is 59/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Arctic Bioscience AS (FRA:9TD), the current ROCE % is -15.76% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arctic Bioscience AS (FRA:9TD) Overvalued in 2026?

Based on GuruFocus' analysis, Arctic Bioscience AS stock appears to be undervalued. The current stock price of €0.24 is trading 76.2% below its estimated GF Value™ of €1.02. GuruFocus considers Arctic Bioscience AS to be Possible Value Trap.

Key valuation signals for FRA:9TD:

  • ROCE %: -15.76%
  • GF Value™: €1.02 vs. price of €0.24 (76.2% below fair value)
  • GF Score™: 59/100 with 6 warning signs

No single metric tells the full story. See the FRA:9TD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arctic Bioscience AS Business Description

Other Exchanges ABS:Norway
Address Industrivegen 42, Orsta, NOR, 6155
Arctic Bioscience AS is a clinical-stage biotechnology company working to develop drug candidates within the areas of autoimmune and inflammatory diseases. It is developing pharmaceutical and commercializing nutraceutical products based on bioactive marine compounds, including lipids essential to maintaining cell membranes. The company's proprietary extraction technology is used to extract membrane fats from marine raw materials, such as herring roe and algae. Geographically, the company operates in Norway, the Americas, Europe, and APAC, with the majority of the revenue derived from the Americas.
59GF Score

Get the complete analysis for FRA:9TD

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.24
Price
€1.02
GF Value